Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine

AIDS

Volumn 17, Issue 11, 2003, Pages 1659-1665

  Stringer, Jeffrey S A ^a,b,c,g   Sinkala, Moses ^a,c,d   Chapman, Victoria ^a   Acosta, Edward P ^a   Aldrovandi, Grace M ^a   Mudenda, Victor ^b,e   Stout, Julia P ^a,c   Goldenberg, Robert L ^a,c   Kumwenda, Rosemary ^f   Vermund, Sten H ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^d MINISTRY OF HEALTH   (Zambia)

^e UNIVERSITY TEACHING HOSPITAL   (Zambia)

^f UNITED NATIONS DEVELOPMENT PROGRAMME   (United States)

^g NONE   (Zambia)

Author keywords

HIV; Nevirapine; Perinatal; Timing; Zambia

Indexed keywords

NEVIRAPINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; LABOR; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN MORBIDITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFANT, NEWBORN; LABOR, OBSTETRIC; NEVIRAPINE; OBSTETRIC LABOR COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TIME FACTORS;

EID: 0043129064     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307250-00010     Document Type: Article

References (21)

1. UNAIDS. Report on the global HIV/AIDS epidemic: July 2002. Geneva: UNAIDS;, 2002.
2. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283: 175-82.
3. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
4. Fowler M, Mwatha A, Guay L, Musoke P, Mmiro F, Fleming T, et al. Effect of nevirapine (NVP) for perinatal HIV prevention appears greatest among women with most advanced disease: subgroup analyses of HIVNET 012. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, February 2002 [abstract 120].
5. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-486.
6. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in Human Immunodeficiency Virus type 1-infected pregnant women and their neonates. J Infect Dis 1998; 178:368-374.
7. Buyse D, Nuwaha F, Karlin T, Wlifert C. Prevention of mother to child HIV transmission: from research to action. XIV International AIDS Conference. Barcelona, Spain, July 2002 [abstract TuPeF5413].
8. World Health Organization. Use of nevirapine for the prevention of mother-to-child transmission of HIV among women of unknown serostatus: Report of a technical consultation. Geneva: WHO Press; 2002.
9. Shetty A, Coovadia H, Maldonado Y, Karim S, Mirochnick M. HIVNET023 - a phase I/II study of the safety and plasma concentrations of nevirapine given daily, twice a week, or weekly as HIV prophlaxis in breastfeeding infants from birth to 24 weeks in Durban, South Africa and Harare, Zimbabwe. Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda; September 2001 [abstract 123].
10. Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan J. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Ped Infect Dis J 2001; 20:803-805.
11. Stringer JSA, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr 2003; 32: 506-513.
12. Stringer J, Sinkala M, Goldenberg R, Stout J, Kumwenda R, Mwinga K, et al. A pilot study of nevirapine administered upon presentation in labor without HIV testing. Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda, September 2001 [abstract 300].
13. McKenna SL, Muyinda GK, Roth D, Mwali M, Ng'andu N, Myrick A, et al. Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS 1997; 11:S103-S110.
14. Paxton H PM, Denton G, McGonigle AD, Meisner PS, Phair JP. Comparison of CD4 cell count by a simple enzyme-linked immunosorbent assay using the TRAx CD4 test kit and by flow cytometry and hematology. Clin Diag Lab Immunol 1995; 2:104-114.
15. Redline R, Wilson-Costello D, Borawski E, Fanaroff A, Hack M. The relationship between placental and other perinatal risk factors for neurologic impairment in very low birth weight children. Ped Res 2000; 47:721-726.
16. Dailly E, Thomas L, Kergueris M, Jolliet P, Bourin M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. J Chromatogr B Biomed Sci Appl 2001; 758:129-135.
17. Beck IA, Drennan KD, Melvin AJ, Mohan KM, Herz AM, Alarcón J, et al. Simple, sensitive, and specific detection of Human Immunodeficiency Virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the field. J Clin Microbiol 2001; 39:29-33.
18. Bryson Y, Luzuriaga K, Sullivan J, Wara D. Proposed definitions for in utero versus intrapartum transmission of HIV-1 [letter]. N Engl J Med 1992; 327:1246-1247.
19. Nakabiito C, Guay L, Musoke P, Fleming T, Jackson J, Mmiro F, et al. Effect of nevirapine (NVP) for perinatal HIV prevention appears strong among women with advanced disease: subgroup analysis of HIVNET 012. XIV International AIDS Conference. Barcelona, Spain, July 2002 [abstract TuOrB1174].
20. Shaffer N, Perre PVd, Vincenzi Id, Bertolli J. Infant-feeding patterns and HIV-1 transmission [letter]. Lancet 1999; 354:1901.
21. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia H. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. Lancet 1999; 354:471-476.